ImmunoBiochem has pioneered a proprietary technology that enables the development of antibody-drug conjugates (ADCs) targeted at intracellular tumor antigens. ADCs comprise a novel class of potentiated biological therapeutics. ADCs combine the targeting capabilities of monoclonal antibodies with cytotoxic properties of small molecule cancer drugs to selectively and specifically destroy cancer cells while minimizing damage to normal tissues. ADCs comprise an antibody component linked to a cytotoxic molecule via a stable linker that is uniquely engineered to deliver and release the cytotoxic payload in cancer cells.